Uncategorized
pSivida completes enrollment for phase 3 trial of Medidur for posterior uveitis
pSivida completed the target enrollment of 120 patients in a phase 3 clinical trial of Medidur to treat posterior uveitis, according to a press release.The double-masked study will compare Medidur vs. sham injections on a two-to-one basis to determine recurrence of posterior uveitis within 1 year. Patients are enrolled at centers in the United States, the European Union and India.